J
Jeffrey H. Kordower
Researcher at Rush University Medical Center
Publications - 351
Citations - 37825
Jeffrey H. Kordower is an academic researcher from Rush University Medical Center. The author has contributed to research in topics: Parkinson's disease & Substantia nigra. The author has an hindex of 94, co-authored 340 publications receiving 34270 citations. Previous affiliations of Jeffrey H. Kordower include Van Andel Institute & Rush University.
Papers
More filters
Journal ArticleDOI
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease
Sonja Kriks,Jae-Won Shim,Jinghua Piao,Yosif Ganat,Dustin R. Wakeman,Zhi-Zhong Xie,Luis Carrillo-Reid,Gordon Auyeung,Chris Antonacci,Amanda Buch,Lichuan Yang,M. Flint Beal,D. James Surmeier,Jeffrey H. Kordower,Viviane Tabar,Lorenz Studer +15 more
TL;DR: A novel floor-plate-based strategy for the derivation of human DA neurons that efficiently engraft in vivo is presented, suggesting that past failures were due to incomplete specification rather than a specific vulnerability of the cells.
Journal ArticleDOI
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
TL;DR: Fourteen years after transplantation into the striatum of an individual with Parkinson's disease, grafted nigral neurons were found to have Lewy body–like inclusions that stained positively for α-synuclein and ubiquitin and to have reduced immunostaining for dopamine transporter.
Journal ArticleDOI
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease†
C. Warren Olanow,Christopher G. Goetz,Jeffrey H. Kordower,A. Jon Stoessl,Vesna Sossi,Mitchell F. Brin,Kathleen M. Shannon,G. Michael Nauert,Daniel P. Perl,James Godbold,Thomas B. Freeman +10 more
TL;DR: Fetal nigral transplantation currently cannot be recommended as a therapy for PD based on results, and Stratification based on disease severity showed a treatment effect in milder patients.
Journal ArticleDOI
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Jeffrey H. Kordower,Marina E. Emborg,Jocelyne Bloch,Shuang Y. Ma,Yaping Chu,Liza Leventhal,Jodi L. McBride,Er-Yun Chen,Stéphane Palfi,Ben Roitberg,W. Douglas Brown,James E. Holden,Robert W. Pyzalski,Michael D. Taylor,Paul M. Carvey,Zaodung Ling,Didier Trono,Philippe Hantraye,Nicole Déglon,Patrick Aebischer,Patrick Aebischer +20 more
TL;DR: Data indicate that GDNF delivery using a lentiviral vector system can prevent nigrostriatal degeneration and induce regeneration in primate models of PD and might be a viable therapeutic strategy for PD patients.
Journal ArticleDOI
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Mark H. Tuszynski,Mark H. Tuszynski,Leon J. Thal,Leon J. Thal,Mary Pay,David P. Salmon,Hoi Sang U,Roy A.E. Bakay,Piyush M. Patel,Armin Blesch,H. Lee Vahlsing,H. Lee Vahlsing,Gilbert Ho,Gang Tong,Steven G. Potkin,James H. Fallon,Lawrence A. Hansen,Elliott J. Mufson,Jeffrey H. Kordower,Christine M. Gall,James M. Conner +20 more
TL;DR: A phase 1 trial of ex vivo NGF gene delivery in eight individuals with mild Alzheimer disease, implanting autologous fibroblasts genetically modified to express human NGF into the forebrain found no long-term adverse effects and brain autopsy from one subject suggested robust growth responses to NGF.